A longitudinal sampling study of transcriptomic and epigenetic profiles in patients with thrombocytopenia syndrome

Yafen Wang, Shaoqing Han, Ruoxi Ran, Anling Li, Huanyu Liu, Mingjun Liu, Yongwei Duan, Xiong Zhang, Zhigang Zhao, Shihui Song, Xiaocheng Weng (), Song-Mei Liu () and Xiang Zhou ()
Additional contact information
Yafen Wang: Wuhan University
Shaoqing Han: Wuhan University
Ruoxi Ran: Zhongnan Hospital of Wuhan University
Anling Li: Zhongnan Hospital of Wuhan University
Huanyu Liu: Zhongnan Hospital of Wuhan University
Mingjun Liu: Zhongnan Hospital of Wuhan University
Yongwei Duan: Zhongnan Hospital of Wuhan University
Xiong Zhang: Wuhan University
Zhigang Zhao: Zhongnan Hospital of Wuhan University, Wuhan University
Shihui Song: Zhongnan Hospital of Wuhan University, Wuhan University
Xiaocheng Weng: Wuhan University
Song-Mei Liu: Zhongnan Hospital of Wuhan University
Xiang Zhou: Wuhan University

Nature Communications, 2021, vol. 12, issue 1, 1-11

Abstract: Abstract Severe fever with thrombocytopenia syndrome (SFTS) is a novel tick-borne infectious disease caused by a new type of SFTS virus (SFTSV). Here, a longitudinal sampling study is conducted to explore the differences in transcript levels after SFTSV infection, and to characterize the transcriptomic and epigenetic profiles of hospitalized patients. The results reveal significant changes in the mRNA expression of certain genes from onset to recovery. Moreover, m6A-seq reveals that certain genes related with immune regulation may be regulated by m6A. Besides the routine tests such as platelet counts, serum ALT and AST levels testing, distinct changes in myocardial enzymes, coagulation function, and inflammation are well correlated with the clinical data and sequencing data, suggesting that clinical practitioners should monitor the above indicators to track disease progression and guide personalized treatment. In this study, the transcript changes and RNA modification may lend a fresh perspective to our understanding of the SFTSV and play a significant role in the discovery of drugs for effective treatment of this disease.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25804-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25804-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25804-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().